Stock A006280 GC BIOPHARMA CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials GC Biopharma Corp.

Equities

A006280

KR7006280002

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 29/04/2024 am IST 		5-day change 1st Jan Change
1,15,100 KRW +2.86% Intraday chart for GC Biopharma Corp. +2.77% -8.29%
20/03 GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI) CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 15,12,246 46,33,750 24,88,073 14,78,007 14,32,354 13,13,657 - -
Enterprise Value (EV) 2 1,820 4,890 2,808 1,948 1,432 1,931 1,876 1,969
P/E ratio -415 x 57.2 x 20.2 x 22.6 x -53.8 x 45.9 x 27.7 x 22.9 x
Yield 0.75% 0.37% 0.92% 1.54% - 1.48% 1.48% 1.3%
Capitalization / Revenue 1.1 x 3.08 x 1.62 x 0.86 x 0.88 x 0.75 x 0.71 x 0.68 x
EV / Revenue 1.33 x 3.25 x 1.83 x 1.14 x 0.88 x 1.11 x 1.01 x 1.03 x
EV / EBITDA 22.8 x 49.4 x 21.7 x 13.3 x 13 x 14.4 x 11.7 x 12.1 x
EV / FCF -20.9 x -104 x 119 x 31.9 x - -7,722 x 34 x 49.2 x
FCF Yield -4.79% -0.96% 0.84% 3.14% - -0.01% 2.94% 2.03%
Price to Book 1.44 x 4.14 x 1.95 x 1.11 x - 1.01 x 0.95 x 0.94 x
Nbr of stocks (in thousands) 11,413 11,413 11,413 11,413 11,413 11,413 - -
Reference price 3 1,32,500 4,06,000 2,18,000 1,29,500 1,25,500 1,15,100 1,15,100 1,15,100
Announcement Date 11/02/20 09/02/21 14/02/22 14/02/23 31/01/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,370 1,504 1,538 1,711 1,627 1,744 1,855 1,919
EBITDA 1 79.94 99.04 129.6 146.4 110.3 133.7 160 163
EBIT 1 40.26 50.25 73.66 81.26 34.44 62.77 88.77 100
Operating Margin 2.94% 3.34% 4.79% 4.75% 2.12% 3.6% 4.79% 5.21%
Earnings before Tax (EBT) 1 -6.142 104.5 172.6 85.73 -27.13 44.74 68.37 94
Net income 1 -3.638 89.27 136.9 65.45 -19.81 29.18 48.58 59
Net margin -0.27% 5.94% 8.91% 3.82% -1.22% 1.67% 2.62% 3.07%
EPS 2 -319.0 7,101 10,796 5,735 -2,333 2,507 4,158 5,035
Free Cash Flow 3 -87,163 -46,902 23,658 61,158 - -250 55,140 40,000
FCF margin -6,363.62% -3,118.25% 1,538.39% 3,573.76% - -14.33% 2,973.23% 2,084.42%
FCF Conversion (EBITDA) - - 18,259.27% 41,786.24% - - 34,462.5% 24,539.88%
FCF Conversion (Net income) - - 17,274.74% 93,438.17% - - 1,13,495.72% 67,796.61%
Dividend per Share 2 1,000 1,500 2,000 2,000 - 1,708 1,708 1,500
Announcement Date 11/02/20 09/02/21 14/02/22 14/02/23 31/01/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 465.7 402.3 416.9 423.2 459.7 411.5 349.5 432.9 439.4 404.9 374.8 461.9 479 428.8 378
EBITDA 1 - - - - - - - - - - 29.6 42 39.8 13.8 -
EBIT 1 71.5 -13.94 41.8 13.1 48.8 -22.41 -13.6 23.7 32.8 -8.406 7.933 19 29.85 4.35 3
Operating Margin 15.35% -3.46% 10.03% 3.1% 10.62% -5.45% -3.89% 5.47% 7.46% -2.08% 2.12% 4.11% 6.23% 1.01% 0.79%
Earnings before Tax (EBT) 1 79.6 59.29 - 12.3 58.7 -17.61 -21 6.3 16.8 -29.25 -13.4 9 35 13 -1
Net income 1 53.7 65.45 - 12.9 37.5 8.621 - 1.8 13.9 -19.87 4.067 6.75 16.7 3.2 -1
Net margin 11.53% 16.27% - 3.05% 8.16% 2.1% - 0.42% 3.16% -4.91% 1.09% 1.46% 3.49% 0.75% -0.26%
EPS - - - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 01/11/21 14/02/22 02/05/22 01/08/22 01/11/22 14/02/23 02/05/23 01/08/23 01/11/23 31/01/24 - - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 308 256 320 470 - 617 562 655
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 3.852 x 2.587 x 2.467 x 3.212 x - 4.613 x 3.513 x 4.018 x
Free Cash Flow 2 -87,163 -46,902 23,658 61,158 - -250 55,140 40,000
ROE (net income / shareholders' equity) -0.35% 7.28% 9.89% 4.53% -1.28% 2.58% 3.92% 4.3%
ROA (Net income/ Total Assets) -0.2% 4.34% 5.34% 2.62% - 1.25% 2.06% 2.6%
Assets 1 1,837 2,055 2,564 2,494 - 2,335 2,358 2,269
Book Value Per Share 3 91,888 98,003 1,11,693 1,16,370 - 1,14,195 1,21,085 1,22,084
Cash Flow per Share 3,530 3,152 11,038 10,440 - - - -
Capex 1 127 82.9 102 58 - 57.4 76.5 -
Capex / Sales 9.31% 5.51% 6.65% 3.39% - 3.29% 4.12% -
Announcement Date 11/02/20 09/02/21 14/02/22 14/02/23 31/01/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for GC Biopharma Corp.

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1,15,100 KRW
Average target price
1,44,667 KRW
Spread / Average Target
+25.69%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GC BIOPHARMA CORP. Stock GC Biopharma Corp.
-8.29% 955M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 664B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.70% 567B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 330B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.42% 234B
NOVARTIS AG Stock Novartis AG
+4.71% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-10.10% 196B
AMGEN INC. Stock Amgen Inc.
-4.04% 148B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A006280 Stock
  4. Financials GC Biopharma Corp.